Table 4.
Main characteristics and results of the eligible studies for evaluation of metastasis development for nonmetastatic patients.
| Study (author/year) |
Country | Number of patients | Age (y) | ALP cut-off (IU/L) |
Enneking stage | RR (95% CI) | Follow-up (m) Median (range) |
|---|---|---|---|---|---|---|---|
| Smeland et al., 2003 [44] | Norway | 104 | NA | A† | II | 1.66 (0.68–4.07) | 83 (42–124) |
| Han et al., 2012 [37] | China | 177 | 23.2 (5–57) | A§ | II | 2.17 (0.97–4.84) | 87 (8–144) |
| Kim et al., 2014 [45] | Korea | 91 | NA | A§ | IIB | 2.03 (1.04–3.97) | NA |
NA: not available, A: available (see the footnotes for details), RR: relative risk, y: year(s), and m: month(s).
†: ALP cut-off: 2–10 y 350 IU/L; 10–13 y female 400 IU/L; 13–15 y male 500 IU/L; 20–50 y 100 IU/L; other childhood age 300 IU/L.
§: ALP cut-off: >14 y 115.5 IU/L; <14 y 300 IU/L.